SEC Filing Summary: Cara Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Cara Therapeutics, Inc. on March 1, 2022. The filing serves as a current report to announce the Company's financial results for the fourth quarter and the full year ended December 31, 2021. The registrant is an emerging growth company incorporated in Delaware with its principal executive offices in Stamford, Connecticut.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Item 2.02 explicitly states that the detailed financial results are contained in a press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the body of this 8-K text.
Material Changes
No material changes or comparative financial data are detailed within the text of this filing. The document functions solely as a notification that the Q4 and full-year 2021 results have been released to the public via a separate press release.
Guidance, Outlook, and Risks
The filing text contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It includes a standard disclaimer stating that the information furnished pursuant to Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 1, 2022) for actual revenue, net loss, and cash position figures.
- Verify the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol CARA on The Nasdaq Stock Market LLC.
- Note that the financial data in the press release is not legally "filed" under Section 18 of the Exchange Act per the disclaimer in this 8-K.